INTRODUCTION: The purpose of this study is to determine if an earlier age at onset of positive symptoms in schizophrenia is associated with cannabis use disorders (CUD). METHODS:49 first-episode schizophrenia subjects with CUD were compared to 51 first-episode schizophrenia subjects with no substance use disorders for demographic and clinical variables. A multivariate logistic regression was performed to determine the joint relationship between variables significantly associated with CUD on univariate testing and ascertain if these variables independently predict CUD. Significance level was set at p<0.05. RESULTS: 74% of CUD subjects had the onset of CUD before the onset of positive symptoms. Compared to non-substance abusing subjects, CUD subjects were predominantly male, younger at study entry, had an earlier age at onset of positive symptoms, less educational attainment, a lower self-socioeconomic status, better premorbid childhood social adjustment, a trend for poorer premorbid childhood academic adjustment, less motor abnormalities but more severe hallucinations and delusions. In the multivariate analysis, only male gender, worse socio-economic status, better premorbid childhood social adjustment, and more severe positive symptoms at study entry were associated with a lifetime history of CUD. DISCUSSION: Although cannabis use precedes the onset of illness in most patients, there was no significant association between onset of illness and CUD that was not accounted for by demographic and clinical variables. Previous studies implicating CUD in the onset of schizophrenia may need to more comprehensively assess the relationship between CUD and schizophrenia, and take into account additional variables that we found associated with CUD. (c) 2010 Elsevier B.V. All rights reserved.
RCT Entities:
INTRODUCTION: The purpose of this study is to determine if an earlier age at onset of positive symptoms in schizophrenia is associated with cannabis use disorders (CUD). METHODS: 49 first-episode schizophrenia subjects with CUD were compared to 51 first-episode schizophrenia subjects with no substance use disorders for demographic and clinical variables. A multivariate logistic regression was performed to determine the joint relationship between variables significantly associated with CUD on univariate testing and ascertain if these variables independently predict CUD. Significance level was set at p<0.05. RESULTS: 74% of CUD subjects had the onset of CUD before the onset of positive symptoms. Compared to non-substance abusing subjects, CUD subjects were predominantly male, younger at study entry, had an earlier age at onset of positive symptoms, less educational attainment, a lower self-socioeconomic status, better premorbid childhood social adjustment, a trend for poorer premorbid childhood academic adjustment, less motor abnormalities but more severe hallucinations and delusions. In the multivariate analysis, only male gender, worse socio-economic status, better premorbid childhood social adjustment, and more severe positive symptoms at study entry were associated with a lifetime history of CUD. DISCUSSION: Although cannabis use precedes the onset of illness in most patients, there was no significant association between onset of illness and CUD that was not accounted for by demographic and clinical variables. Previous studies implicating CUD in the onset of schizophrenia may need to more comprehensively assess the relationship between CUD and schizophrenia, and take into account additional variables that we found associated with CUD. (c) 2010 Elsevier B.V. All rights reserved.
Authors: Emily Thaden; Joseph P Rhinewine; Todd Lencz; Hana Kester; Kelly L Cervellione; Inika Henderson; David Roofeh; Katherine E Burdick; Barbara Napolitano; Barbara A Cornblatt; Sanjiv Kumra Journal: Schizophr Res Date: 2005-11-23 Impact factor: 4.939
Authors: Darryl Wade; Susy Harrigan; Jane Edwards; Philip M Burgess; Greg Whelan; Patrick D McGorry Journal: Schizophr Res Date: 2005-11-17 Impact factor: 4.939
Authors: A L Hoff; D Harris; W O Faustman; M Beal; D DeVilliers; R D Mone; J A Moses; J G Csernansky Journal: Schizophr Res Date: 1996-05 Impact factor: 4.939
Authors: Mary E Kelley; Claire Ramsay Wan; Beth Broussard; Anthony Crisafio; Sarah Cristofaro; Stephanie Johnson; Thomas A Reed; Patrick Amar; Nadine J Kaslow; Elaine F Walker; Michael T Compton Journal: Schizophr Res Date: 2016-01-17 Impact factor: 4.939
Authors: Laura Ferraro; Caterina La Cascia; Diego Quattrone; Lucia Sideli; Domenica Matranga; Veronica Capuccio; Giada Tripoli; Charlotte Gayer-Anderson; Craig Morgan; Musa B Sami; Pak Sham; Lieuwe de Haan; Eva Velthorst; Hannah E Jongsma; James B Kirkbride; Bart P F Rutten; Alexander L Richards; Laura Roldan; Celso Arango; Miquel Bernardo; Julio Bobes; Julio Sanjuan; Jose Luis Santos; Manuel Arrojo; Ilaria Tarricone; Andrea Tortelli; Andrei Szöke; Cristina Marta Del-Ben; Jean-Paul Selten; Michael Lynskey; Peter B Jones; Jim Van Os; Daniele La Barbera; Robin M Murray; Marta Di Forti Journal: Schizophr Bull Date: 2020-04-10 Impact factor: 9.306
Authors: Ricardo Coentre; Alexandra Fonseca; Tiago Mendes; Ana Rebelo; Elisabete Fernandes; Pedro Levy; Carlos Góis; Maria Luísa Figueira Journal: Ann Gen Psychiatry Date: 2021-07-06 Impact factor: 3.455
Authors: Melissa A Weibell; Inge Joa; Jørgen Bramness; Jan Olav Johannessen; Patrick D McGorry; Wenche Ten Velden Hegelstad; Tor Ketil Larsen Journal: BMC Psychiatry Date: 2013-11-27 Impact factor: 3.630